Table 3.
Association between the target gene mutations and several clinicopathological variables
| For KRAS gene mutations only | ||||
| Variables | Cases | Wild Type (n = 42) | Mutant (n = 4) | p-value (Fisher’s exact test) |
| Age (yr) | ||||
| 30–45 | 26 | 25 | 1 | 0.303 |
| > 45 | 20 | 17 | 3 | |
| HPV infections | ||||
| HPV 16 | 21 | 18 | 3 | 0.672 |
| HPV 18 | 7 | 7 | 0 | |
| HPV 16 & 18 | 17 | 16 | 1 | |
| Negative | 1 | 1 | 0 | |
| FIGO stage | ||||
| IA | 14 | 11 | 3 | 0.136 |
| IB | 20 | 20 | 0 | |
| IIA | 8 | 7 | 1 | |
| IIB | 4 | 4 | 0 | |
| For PIK3CA gene mutations only | ||||
| Variables | Cases | Wild Type (n = 29) | Mutant (n = 17) | p-value (Fisher’s exact test) |
| Age (yr) | ||||
| 30–45 | 26 | 15 | 11 | 0.538 |
| > 45 | 20 | 14 | 6 | |
| HPV infections | ||||
| HPV 16 | 21 | 15 | 6 | 0.480 |
| HPV 18 | 7 | 3 | 4 | |
| HPV 16 & 18 | 17 | 10 | 7 | |
| Negative | 1 | 1 | 0 | |
| FIGO stage | ||||
| IA | 14 | 8 | 6 | 0.788 |
| IB | 20 | 13 | 7 | |
| IIA | 8 | 6 | 2 | |
| IIB | 4 | 2 | 2 | |
| For EGFR gene mutations only | ||||
| Variables | Cases | Wild Type (n = 37) | Mutant (n = 9) | p-value (Fisher’s exact test) |
| Age (yr) | ||||
| 30–45 | 26 | 20 | 6 | 0.711 |
| > 45 | 20 | 17 | 3 | |
| HPV infections | ||||
| HPV 16 | 21 | 17 | 4 | 0.391 |
| HPV 18 | 7 | 6 | 1 | |
| HPV 16 & 18 | 17 | 14 | 3 | |
| Negative | 1 | 0 | 1 | |
| FIGO stage | ||||
| IA | 14 | 11 | 3 | 0.291 |
| IB | 20 | 14 | 6 | |
| IIA | 8 | 8 | 0 | |
| IIB | 4 | 4 | 0 | |
| Considering all gene mutations | ||||
| Variables | Cases | Wild-Type (n = 20) | Mutant (n = 26) | p-value (Fisher’s exact test) |
| Age (yr) | ||||
| 30–45 | 26 | 11 | 15 | > 0.999 |
| > 45 | 20 | 9 | 11 | |
| HPV infections | ||||
| HPV 16 | 21 | 10 | 11 | 0.955 |
| HPV 18 | 7 | 3 | 4 | |
| HPV 16 & 18 | 17 | 7 | 10 | |
| Negative | 1 | 0 | 1 | |
| FIGO stage | ||||
| IA | 14 | 4 | 10 | 0.480 |
| IB | 20 | 9 | 11 | |
| IIA | 8 | 5 | 3 | |
| IIB | 4 | 2 | 2 | |